Pancreatic Patients targeted to benefit from IMM-101

About Pancreatic ductal adenocarcinoma (PDAC)

Pancreatic cancer has the highest mortality of any solid tumor with patients diagnosed late having <5% chance of survival after 5 years. PDAC represents 95% of all PC, often associated with low infiltration of tumor CD8+ T cells and an immunosuppressive microenvironment characteristic of a poor type I immune response. Elderly pancreatic cancer patients and younger patients who are not able to tolerate more intensive treatments such as FOLFIRINOX have very few treatment options to help manage their disease.

Current systemic treatment options include chemotherapy and radiation that have limited efficacy and high toxicity in this setting. Current standard of care for these patients is gemcitabine plus Abraxane (nab-paclitaxel). Targeted immunotherapies have been largely unsuccessful in this cancer type.

IMM-101 Addresses a Significant Unmet medical need in PDAC

Immodulon has generated promising phase II data with IMM-101 in first line patients with advanced pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine (IMAGE-1 study). These data show that IMM-101 is well-tolerated and effective, with the potential to prolong progression-free survival for patients compared to gemcitabine alone. The data also suggest a beneficial effect on survival in patients with metastatic disease.

Immodulon is currently prioritizing the initiation of a Phase III Bayesian adaptive platform study for IMM-101 in PDAC that can be expanded to evaluate IMM-101 in other immunologically ‘cold’ tumours across multiple parallel arms.